Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Sponsor: Hoffmann-La Roche
Summary
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Official title: An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-06-01
Completion Date
2033-03-01
Last Updated
2026-03-13
Healthy Volunteers
No
Conditions
Interventions
Ipatasertib
Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Tiragolumab
Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Atezolizumab
Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study.
Tiragolumab and Atezolizumab
Tiragolumab and Atezolizumab in fixed dose combination administered intravenously (IV) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Bevacizumab
Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Entrectinib
Entrectinib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Inavolisib
Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Divarasib
Divarasib will be administered as a monotherapy or in combination with atezolizumab or bevacizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Locations (57)
GHdC Site Les Viviers
Charleroi, Belgium
AZ Groeninge
Kortrijk, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Princess Margaret Cancer Center
Toronto, Ontario, Canada
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
XI 'an City, Shaanxi Province, Shaanxi, China
Beijing Cancer Hospital
Beijing, China
The First Hospital of Jilin University
Changchun, China
West China Hospital of Sichuan University
Chengdu, China
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
The Second Affiliated Hospital of Anhui Medical University
Hefei, China
Meizhou People's Hospital
Meizhou, China
The 1st Affiliated Hospital of Nanchang Unversity
Nanchang, China
Jiangsu Province Hospital of Chinese Medicine
Nanjing, China
Fudan University Shanghai Cancer Center
Shanghai, China
Shanghai Geriatric Medical Center
Shanghai, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China
Henan Cancer Hospital
Zhengzhou, China
Clinica CIMCA
San José, Costa Rica
ICIMED Instituto de Investigación en Ciencias Médicas
San José, Costa Rica
Institut Bergonie
Bordeaux, France
Centre Francois Baclesse
Caen, France
Institut de Cancérologie de Bourgogne
Dijon, France
Hopital de la Timone
Marseille, France
Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque
Montpellier, France
Institut de cancerologie du Gard
Nîmes, France
Hopital Tenon
Paris, France
ICO - Site René Gauducheau
Saint-Herblain, France
Institut Claudius Regaud
Toulouse, France
Gustave Roussy
Villejuif, France
General Hospital "G.Papanikolaou"
Asvestochóri, Greece
Metropolitan General Hospital
Cholargós, Greece
Kyushu University Hospital
Fukuoka, Japan
Yokohama City University Medical Center
Kanagawa, Japan
Kanagawa Cancer Center
Kanagawa, Japan
National Cancer Center Hospital East
Kashiwa-shi, Japan
Saitama Cancer Center
Saitama, Japan
NHO Kinki-Chuo Chest Medical Center
Sakaishi, Japan
Centro Medico Culiacan SA de CV
Culiacán, Sinaloa, Mexico
Medical Care & Research
Mérida, Yucatán, Mexico
Consultorio de Especialidad en Urologia Privado
Durango, Mexico
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie
Warsaw, Poland
Moscow City Oncology Hospital #62
Moscovskaya Oblast, Moscow Oblast, Russia
Russian Scientific Center of Roentgenoradiology
Moscow, Moscow Oblast, Russia
P.A. Herzen Oncological Inst.
Moscow, Moscow Oblast, Russia
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Asan Medical Center
Seoul, South Korea
Taichung Veterans General Hospital
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Chang Gung Memorial Hospital - Linkou
Taoyuan District, Taiwan
Chulalongkorn Hospital
Bangkok, Thailand
Siriraj Hospital
Bangkok, Thailand
Maharaj Nakorn Chiangmai Hospital
Chiang Mai, Thailand
Leicester Royal Infirmary
Leicester, United Kingdom
Royal Marsden Hospital - Surrey
Surrey, United Kingdom